Topics

Pharming deal shows there's still life in struggling cancer drug class

07:55 EDT 15 Aug 2019 | BioPharmaDive

For $20 million, the Netherlands-based company gets access to leniolisib, a PI3K inhibitor developed by Novartis.

Original Article: Pharming deal shows there's still life in struggling cancer drug class

NEXT ARTICLE

More From BioPortfolio on "Pharming deal shows there's still life in struggling cancer drug class"

Quick Search

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...